BETHESDA, Md., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced that Dr. Claire Kruger, Chief Executive Officer, and Dr. Robert Lodder, President, will be presenting a corporate overview at the Rodman & Renshaw 14th Annual Healthcare Conference at 11:40 a.m. Eastern time on Monday, September 10, in the North Foyer of the Waldorf Astoria in New York. The overview will introduce the Spherix DDDAS combination drug development platform, and reveal how the platform led to the latest advances in the SPX106T development program, including new uses of SPX106T to slow the growth rate of abdominal aortic aneurysms as well as to treat other diseases with inflammatory components.
